DEF: Select Medical to Vote on Board Declassification, Special Meeting Rights

Select Medical Holdings Corporation announces its 2026 Annual Meeting of Stockholders to address director elections, executive compensation, auditor ratification, board declassification, and special meeting rights.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on April 23, 2026, at 11:00 a.m. EDT, with a record date for voting of February 27, 2026.
• Key proposals include the election of three Class II directors, a non-binding advisory vote on named executive officer compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026.
• Stockholders will vote on an amendment to phase out the classified Board structure by 2028, aiming for all directors to be elected annually.
• Two non-binding advisory votes are scheduled regarding stockholders' right to call a special meeting: a Company proposal for a 25% ownership threshold and a stockholder proposal for a 10% ownership threshold.
• The Board of Directors recommends voting FOR all proposals except the 10% special meeting threshold (Proposal 6), which it recommends AGAINST.
• For fiscal year 2025, the company achieved adjusted earnings per share of $1.16 and a return on equity of 8.6%, resulting in named executive officer bonuses equaling 190% of target.
• Executive Chairman Robert A. Ortenzio made a non-binding offer on November 24, 2025, to acquire all outstanding shares for cash consideration of $16.00 to $16.20 per share, which an independent special committee is currently reviewing.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautious outlook due to the significant decline in key financial metrics and stock price over the past few years, despite proposed corporate governance enhancements. The pending take-private offer at a price below recent historical highs adds to the uncertainty.

Positives

• The Board of Directors is composed of ten highly experienced, talented, and qualified directors, with 8 out of 10 determined to be independent.
• The company has a Lead Director (Russell L. Carson) to enhance independent oversight and communication between the Chairman and independent directors.
• Strong corporate governance practices are in place, including separate CEO and Chairman roles, annual say-on-pay, majority voting for director elections, and key committees consisting wholly of independent directors.
• The company has not experienced a material cybersecurity breach or information security breach during the past three fiscal years, demonstrating effective information security programs.
• All named executive officers satisfied stock ownership guidelines as of December 31, 2025, which aligns their long-term interests with those of stockholders.
• Stockholders approved the executive compensation program at the last annual meeting with approximately 91% of votes in favor, indicating strong support for the current approach.
• The company achieved adjusted earnings per share of $1.16 and a return on equity of 8.6% for fiscal year 2025, exceeding target levels for executive bonuses.

Negatives

• The Board recommends against a stockholder proposal for a 10% ownership threshold to call a special meeting, preferring a 25% threshold, which some shareholders may view as less shareholder-friendly.
• The company's three largest stockholders collectively own a significant portion (14.1%, 12.9%, and 10.5%) of outstanding common stock, raising concerns about disproportionate influence if a lower special meeting threshold were adopted.
• Executive compensation includes tax gross-up payments for certain named executive officers in the event of a change in control, although the Board has adopted a policy to prohibit this in future agreements.
• The company's stock price has declined from $29.40 on December 31, 2021, to $14.85 on December 31, 2025, indicating a significant decrease in shareholder return over the period.
• Net income has decreased from $499.95 million in 2021 to $214.53 million in 2025.
• Earnings Per Share (EPS) has decreased from $2.98 in 2021 to $1.16 in 2025.

Risks

• The company faces regulatory risk, credit risk, liquidity risk, reputational risk, risk from adverse fluctuations in interest rates, and information security risks, including cybersecurity risk.
• Financial performance is heavily dependent upon the constantly changing and complex regulatory environment, including changes in Medicare payment rates and formulae.
• There is a potential for abuse of the right to call a special meeting by a small number of stockholders if the threshold is too low, which could lead to significant administrative and operational costs and distraction for management.
• The scope and impact of any future cybersecurity incident cannot be predicted, despite current insurance and preventative measures.
• There is no guarantee that the non-binding Take-Private Proposal by Robert A. Ortenzio will be accepted by the Special Committee, that definitive documentation will be executed, or that a transaction will be consummated, creating uncertainty for the company and its stockholders.

Future Outlook

The Board of Directors will continue to periodically review its leadership structure, recognizing that other models may become more appropriate depending on future circumstances. The company intends to announce preliminary voting results at the Annual Meeting and publish final results in a Current Report on Form 8-K within four business days. The declassification of the Board of Directors would be phased out commencing with the 2026 Annual Meeting, resulting in all directors standing for annual elections by the 2028 Annual Meeting if approved. An independent special committee is evaluating the Take-Private Proposal and other potential strategic alternatives to maximize stockholder value.

Management Comments

• "We consider your vote important and encourage you to vote as soon as possible." (John F. Duggan, Executive Vice President, General Counsel and Secretary)
• "The Board of Directors has carefully considered its leadership structure and believes at this time that the Company and its stockholders are best served by having the positions of Executive Chairman and Chief Executive Officer filled by different individuals."
• "The Compensation Committee has concluded that the Company's compensation policies and programs are not reasonably likely to have a material adverse effect on the Company."
• "The Company believes that these guidelines ensure that NEOs hold a sufficient amount of the Company's common stock to further strengthen the long-term link between the results achieved for the Company's stockholders and the compensation provided to the NEOs." (Regarding stock ownership guidelines)
• "The Company believes that this benefit [tax gross-up payment] is appropriate to ensure that, in the event of a potential change in control, the NEOs are focused on closing the change in control transaction and maximizing stockholder value."
• "The Compensation Committee believes that this level of overall compensation and mix of compensation elements for each properly reflects the very valuable, yet very different roles that each of Mr. Ortenzio and Mr. Chernow play for the Company, and is consistent with the Company's overall compensation philosophy." (Regarding compensation of Executive Chairman and Vice Chairman)
• "The Compensation Committee believed that its historical approach to executive compensation decisions was appropriate and therefore did not engage a compensation consultant." (For 2025 fiscal year)
• "The Company believes that its executive compensation program has played an essential role in its continuing financial success by aligning the long-term interests of its NEOs with the long-term interests of its stockholders."
• "The Board of Directors believes that the special meeting right in this Proposal 6 is not in the best interests of the Company and its stockholders and is not consistent with market practice or best corporate governance practices." (Regarding 10% special meeting threshold)
• "The Company believes that a more accurate disclosure would exclude on-call employees who have no set work schedule and work only on an as-needed basis, which may be a few times a year." (Regarding pay ratio calculation)

Industry Context

StockSavvy.ai notes that the healthcare industry is subject to a constantly changing and complex regulatory environment, particularly concerning Medicare payment rates. This volatility influences executive compensation structures, leading the company to favor time-based equity vesting over performance-based vesting to mitigate disincentives caused by external factors. The company's emphasis on cybersecurity, structured around the NIST framework and HIPAA Security Risk Assessment Tool, reflects a critical industry-wide focus on data protection and regulatory compliance in healthcare. The discussion around board declassification and special meeting thresholds indicates a broader trend in corporate governance where companies are increasingly responding to shareholder activism and evolving best practices, balancing continuity with accountability.

Comparison to Industry Standards

• The Board believes a 25% ownership threshold for calling a special meeting is "consistent with market practice for corporate governance programs among many S&P 500 companies."
• The company's executive compensation program was approved by approximately 91% of votes cast at the last annual meeting, suggesting alignment with shareholder expectations for compensation practices.
• The company's decision to phase out excise tax gross-up payments in future change-in-control agreements aligns with evolving corporate governance best practices that generally discourage such provisions.
• The company's stock performance (TSR) and financial metrics (Net Income, EPS) have shown a downward trend from 2021 to 2025. The company's cumulative Total Shareholder Return (TSR) of $114.38 (based on an initial $100 investment) as of December 31, 2025, underperformed the S&P Health Care Services Select Industry Index (SPSIHP) TSR of $109.97 over the same period, indicating a relative decline in shareholder value compared to its peer group.

Management Changes

Corporate Governance

Related Party Transactions

• The company leases its corporate office space from the Ortenzio Partnerships, which are related parties. In fiscal year 2025, the company paid approximately $8.0 million for office rent and miscellaneous expenses.
• The company has a NetJets Agreement with Robert Ortenzio, allowing the company to use an aircraft leased by Mr. Ortenzio. In fiscal year 2025, Robert Ortenzio received $120,541 from Select under this agreement.
• Robert A. Ortenzio, Executive Chairman, Co-Founder and Director, made a non-binding indication of interest to acquire all outstanding shares of the company for cash consideration of $16.00 to $16.20 per share.

Stakeholder Impact

• Shareholders will vote on key governance proposals (director elections, board declassification, special meeting rights, executive compensation, auditor ratification). The Take-Private Proposal by Robert A. Ortenzio could significantly impact shareholder value, depending on its outcome. The decline in TSR, Net Income, and EPS over recent years directly impacts shareholder returns.
• Employees are impacted by executive compensation policies designed to attract and retain talent. The company provides formalized information security and cybersecurity training for new and existing employees.
• Customers and patients are impacted by the oversight of the Quality of Care and Patient Safety Committee, which reviews policies and procedures relating to the delivery of quality medical care and patient safety.
• Management's compensation is tied to financial performance (EPS, ROE). Management is responsible for day-to-day risk management, including cybersecurity. The Take-Private Proposal introduces uncertainty for management.
• Creditors are impacted by the company's financial performance and risk management practices, including liquidity risk oversight.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on April 23, 2026.
• Elect three Class II directors.
• Hold a non-binding advisory vote on named executive officer compensation.
• Ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026.
• Vote on the approval of an amendment to phase out the classified structure of the Board.
• Hold a non-binding advisory vote on a Company proposal to provide stockholders the right to call a special meeting at a 25% ownership threshold.
• Hold a non-binding advisory vote on a stockholder proposal to provide stockholders the right to call a special meeting of stockholders at a 10% ownership threshold, if properly presented.
• The independent special committee will continue reviewing and evaluating the Take-Private Proposal and other potential strategic alternatives.
• The company will publish final voting results in a Current Report on Form 8-K within four business days following the Annual Meeting.
• The Board of Directors will consider the outcome of the advisory votes on special meeting thresholds when considering whether and how to implement the proposals.
• The declassification of the Board will be phased in, with all directors standing for annual election by the 2028 Annual Meeting if the proposal is approved.

Key Dates

Recommendation

While the company is addressing corporate governance concerns through board declassification and considering enhanced shareholder rights, the significant decline in financial performance (Net Income, EPS, TSR) and stock price over the past few years is a major concern. The pending non-binding take-private offer from the Executive Chairman introduces both potential upside and uncertainty. Given the mixed signals of governance improvements against a backdrop of declining financial results and a pending M&A event, a 'hold' recommendation is appropriate, advising investors to await further clarity on the take-private offer and a reversal in financial trends.

Keywords

Proxy Statement, Corporate Governance, Executive Compensation, Board Declassification, Special Meeting Rights, Shareholder Proposals, SEC Filing, Healthcare Industry, Risk Management, Cybersecurity, Financial Performance, Earnings Per Share, Return on Equity, Take-Private Proposal, Select Medical Holdings Corporation